QQQ   258.54 (-2.06%)
AAPL   381.91 (-0.46%)
MSFT   207.07 (-3.09%)
GOOGL   1,512.23 (-1.74%)
AMZN   3,104.00 (-3.00%)
NVDA   402.09 (-4.07%)
CGC   17.30 (-0.69%)
BABA   251.67 (-3.58%)
MU   49.46 (-2.45%)
GE   6.70 (+0.15%)
TSLA   1,497.06 (-3.08%)
AMD   53.59 (-4.10%)
T   29.76 (-1.23%)
ACB   12.08 (+0.50%)
GILD   76.68 (+0.47%)
DIS   116.22 (-2.61%)
NFLX   525.50 (-4.23%)
BAC   24.19 (+0.71%)
BA   175.65 (-1.56%)
QQQ   258.54 (-2.06%)
AAPL   381.91 (-0.46%)
MSFT   207.07 (-3.09%)
GOOGL   1,512.23 (-1.74%)
AMZN   3,104.00 (-3.00%)
NVDA   402.09 (-4.07%)
CGC   17.30 (-0.69%)
BABA   251.67 (-3.58%)
MU   49.46 (-2.45%)
GE   6.70 (+0.15%)
TSLA   1,497.06 (-3.08%)
AMD   53.59 (-4.10%)
T   29.76 (-1.23%)
ACB   12.08 (+0.50%)
GILD   76.68 (+0.47%)
DIS   116.22 (-2.61%)
NFLX   525.50 (-4.23%)
BAC   24.19 (+0.71%)
BA   175.65 (-1.56%)
QQQ   258.54 (-2.06%)
AAPL   381.91 (-0.46%)
MSFT   207.07 (-3.09%)
GOOGL   1,512.23 (-1.74%)
AMZN   3,104.00 (-3.00%)
NVDA   402.09 (-4.07%)
CGC   17.30 (-0.69%)
BABA   251.67 (-3.58%)
MU   49.46 (-2.45%)
GE   6.70 (+0.15%)
TSLA   1,497.06 (-3.08%)
AMD   53.59 (-4.10%)
T   29.76 (-1.23%)
ACB   12.08 (+0.50%)
GILD   76.68 (+0.47%)
DIS   116.22 (-2.61%)
NFLX   525.50 (-4.23%)
BAC   24.19 (+0.71%)
BA   175.65 (-1.56%)
QQQ   258.54 (-2.06%)
AAPL   381.91 (-0.46%)
MSFT   207.07 (-3.09%)
GOOGL   1,512.23 (-1.74%)
AMZN   3,104.00 (-3.00%)
NVDA   402.09 (-4.07%)
CGC   17.30 (-0.69%)
BABA   251.67 (-3.58%)
MU   49.46 (-2.45%)
GE   6.70 (+0.15%)
TSLA   1,497.06 (-3.08%)
AMD   53.59 (-4.10%)
T   29.76 (-1.23%)
ACB   12.08 (+0.50%)
GILD   76.68 (+0.47%)
DIS   116.22 (-2.61%)
NFLX   525.50 (-4.23%)
BAC   24.19 (+0.71%)
BA   175.65 (-1.56%)
Log in

NASDAQ:SNDXSyndax Pharmaceuticals Stock Price, Forecast & News

$14.39
-0.96 (-6.25 %)
(As of 07/13/2020 04:00 PM ET)
Add
Compare
Today's Range
$14.36
Now: $14.39
$15.62
50-Day Range
$14.46
MA: $15.78
$20.17
52-Week Range
$5.35
Now: $14.39
$21.97
Volume201,011 shs
Average Volume572,837 shs
Market Capitalization$519.41 million
P/E RatioN/A
Dividend YieldN/A
Beta1.83
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company's lead product candidates include entinostat, which is in Phase III clinical trials for the treatment of advanced hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) breast cancer; and SNDX-5613 inhibitor that targets the binding interaction of Menin with mixed lineage leukemia-rearranged and acute myeloid leukemia with a mutated nucleophosmin 1. It also develops entinostat with Keytruda (pembrolizumab) in a Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and melanoma or microsatellite stable colorectal carcinoma; with Tecentriq (atezolizumab) in a Phase Ib/II clinical trials to treat patients with triple-negative breast cancer, and HR+ and HER2- metastatic breast cancer; and with Bavencio (avelumab) in a Phase Ib/II clinical trials for the treatment of ovarian cancer. In addition, the company develops SNDX-6352, a monoclonal antibody that blocks the colony stimulating factor 1 that is in Phase I dose escalation trial in patients with chronic graft versus host disease; and as a monotherapy and in combination with Imfinzi (durvalumab), which is in Phase I/Ib dose trials for the treatment of solid tumors. Syndax Pharmaceuticals, Inc. has clinical collaborations with MSD International GmbH; Genentech, Inc.; Merck KGaA and Pfizer; and AstraZeneca plc. It also has collaborative research and development agreement with National Cancer Institute; clinical trial agreement with Eastern Cooperative Oncology Group; and license agreement with Kyowa Hakko Kirin Co., Ltd. The company was founded in 2005 and is headquartered in Waltham, Massachusetts.
Read More
Syndax Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.58 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SNDX
CUSIPN/A
Phone781-419-1400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.52 million
Book Value$1.16 per share

Profitability

Net Income$-56,050,000.00
Net Margins-4,013.65%

Miscellaneous

Employees38
Market Cap$519.41 million
Next Earnings Date8/5/2020 (Estimated)
OptionableOptionable

Receive SNDX News and Ratings via Email

Sign-up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter.

Syndax Pharmaceuticals (NASDAQ:SNDX) Frequently Asked Questions

How has Syndax Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Syndax Pharmaceuticals' stock was trading at $11.79 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, SNDX shares have increased by 22.1% and is now trading at $14.39. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Syndax Pharmaceuticals?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syndax Pharmaceuticals in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Syndax Pharmaceuticals.

When is Syndax Pharmaceuticals' next earnings date?

Syndax Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Syndax Pharmaceuticals.

How were Syndax Pharmaceuticals' earnings last quarter?

Syndax Pharmaceuticals Inc (NASDAQ:SNDX) posted its quarterly earnings data on Thursday, May, 7th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.51) by $0.05. The company earned $0.38 million during the quarter, compared to analysts' expectations of $0.38 million. Syndax Pharmaceuticals had a negative net margin of 4,013.65% and a negative return on equity of 132.06%. View Syndax Pharmaceuticals' earnings history.

What price target have analysts set for SNDX?

9 Wall Street analysts have issued twelve-month target prices for Syndax Pharmaceuticals' stock. Their forecasts range from $14.00 to $33.00. On average, they expect Syndax Pharmaceuticals' stock price to reach $21.38 in the next twelve months. This suggests a possible upside of 48.5% from the stock's current price. View analysts' price targets for Syndax Pharmaceuticals.

Has Syndax Pharmaceuticals been receiving favorable news coverage?

Media headlines about SNDX stock have trended very negative recently, according to InfoTrie. The research firm rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Syndax Pharmaceuticals earned a news impact score of -3.2 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news about Syndax Pharmaceuticals.

Are investors shorting Syndax Pharmaceuticals?

Syndax Pharmaceuticals saw a increase in short interest in June. As of June 15th, there was short interest totaling 2,890,000 shares, an increase of 28.4% from the May 31st total of 2,250,000 shares. Based on an average trading volume of 849,300 shares, the days-to-cover ratio is currently 3.4 days. Currently, 11.4% of the company's shares are sold short. View Syndax Pharmaceuticals' Current Options Chain.

Who are some of Syndax Pharmaceuticals' key competitors?

What other stocks do shareholders of Syndax Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syndax Pharmaceuticals investors own include Opko Health (OPK), Exelixis (EXEL), Verastem (VSTM), Micron Technology (MU), Inovio Pharmaceuticals (INO), TherapeuticsMD (TXMD), Clearside Biomedical (CLSD), Idera Pharmaceuticals (IDRA), Novavax (NVAX) and TG Therapeutics (TGTX).

Who are Syndax Pharmaceuticals' key executives?

Syndax Pharmaceuticals' management team includes the following people:
  • Dr. Briggs W. Morrison M.D., CEO & Director (Age 59)
  • Mr. Michael A. Metzger, Pres & COO (Age 48)
  • Mr. Richard P. Shea, CFO & Treasurer (Age 67)
  • Dr. Michael L. Meyers, Chief Medical Officer & Sr. VP (Age 68)
  • Dr. Peter Ordentlich, Co-Founder & Chief Scientific Officer (Age 50)

When did Syndax Pharmaceuticals IPO?

(SNDX) raised $66 million in an initial public offering (IPO) on Thursday, March 3rd 2016. The company issued 4,400,000 shares at $14.00-$16.00 per share. Morgan Stanley and Citigroup acted as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.

What is Syndax Pharmaceuticals' stock symbol?

Syndax Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNDX."

How do I buy shares of Syndax Pharmaceuticals?

Shares of SNDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Syndax Pharmaceuticals' stock price today?

One share of SNDX stock can currently be purchased for approximately $14.39.

How big of a company is Syndax Pharmaceuticals?

Syndax Pharmaceuticals has a market capitalization of $519.41 million and generates $1.52 million in revenue each year. The company earns $-56,050,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis. Syndax Pharmaceuticals employs 38 workers across the globe.

What is Syndax Pharmaceuticals' official website?

The official website for Syndax Pharmaceuticals is www.syndax.com.

How can I contact Syndax Pharmaceuticals?

Syndax Pharmaceuticals' mailing address is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. The company can be reached via phone at 781-419-1400 or via email at [email protected]

This page was last updated on 7/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.